Opinion|Videos|July 18, 2024

Impact of JAK Inhibitors on Itch and Quality of Life in Atopic Dermatitis

Shawn Kwatra, MD, provides an overview of oral JAK inhibitors for the treatment of atopic dermatitis, highlighting data from clinical trials.

Video content above is prompted by the following questions:

  • What characteristics, if any, of oral JAK inhibitors make them an attractive option for improving QoL in patients with AD?
  • Discuss clinical trial data with oral JAK inhibitors, upadacitinib and abrocitinib, and improvements in patient-reported outcomes in atopic dermatitis.
    • Please review data from real-world studies that have evaluated effectiveness of oral JAK inhibitors (upadacitinib and abrocitinib) through physician and patient-reported outcomes.

Latest CME